This is a snippet of the transcript, sign up to read more.
At least double that. When we were focusing on that, my average sales price was about $3,500, and we were looking for between $7,000 and $10,000 per unit.
This is a snippet of the transcript, sign up to read more.
The sweet spot is where you're already approved. That's always the sweet spot. Instead of trying to fight with GPOs, IDNs, or hospital systems to get the product approved, which could take three to 12 months, you work where you have low-hanging fruit and opportunities in places where you're already approved. That was the focus. As you build momentum, you aim to get into large teaching institutions like HSS Hospital for Special Surgery. You find a target willing to support you and go through the approval process. Early on, I focused on where I was already approved, where I could sell the product and utilize it quickly.
This is a snippet of the transcript, sign up to read more.
I'd approach the negotiation knowing it's going to be a three to nine-month process. It's not going to happen overnight. I also know I need at least two surgeons to support me and request the product. I have to go in with a lower than usual expectation of pricing, probably 20% to 25% lower than what I would normally get.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.